Is ctmx buy

**CytomX Therapeutics (CTMX) is not a buy according to the analysis.** Here's the detailed analysis:

1. **Analyst Ratings and Price Targets**: The analyst consensus is a Moderate Buy, based on 6 analysts giving stock ratings to CytomX Therapeutics in the past 3 months. The average price target is $5.32, with a high forecast of $8.00 and a low forecast of $3.50. This indicates a significant potential upside from the current price.
2. **Stock Performance and Volatility**: The stock has experienced a recent price increase, with a gain of 5.07% on the last trading day, rising from $1.38 to $1.45. However, the stock has also shown high volatility, with a 5.80% fluctuation in price on the last trading day.
3. **Technical Analysis**: The general sentiment is bearish, with more bearish signals than bullish signals from technical analysis indicators. This suggests that the stock may face downward pressure in the short term.
4. **Strategic Partnerships and Pipeline**: CytomX Therapeutics has entered into strategic partnerships, such as the collaboration with Merck to assess CX-801 in combination with pembrolizumab in various solid tumors. This could be a positive sign for the company's future prospects.
5. **Financial Performance**: The company reported a net gain of $13.8M or $0.17/share, which was higher than expected due to higher than expected revenue recognition, including $10M of milestones earned under the Astellas collaboration. This indicates strong financial performance in the near term.

Given these points, while there is potential for significant upside based on analyst price targets, the bearish sentiment from technical analysis and the recent price volatility suggest that CTMX is not a buy at this time. Investors should exercise caution and consider their investment strategy accordingly.